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Background: Anthroposophic treatment for asthma includes special artistic and physical 
therapies and special medications.
Methods: We studied consecutive outpatients starting anthroposophic treatment for 
asthma under routine conditions in Germany. Main outcomes were average asthma severity 
(0–10, primary outcome); symptoms (1–4); and asthma-related quality of life at 12-month 
follow-up (Asthma Quality of Life Questionnaire [AQLQ] overall score, 1–7, for adults; KINDL 
Questionnaire for Measuring Health-Related Quality of Life in Children and Adolescents, asthma 
module, 0–100, for children) at 12-month follow-up.
Results: Ninety patients (54 adults, 36 children) were included. Anthroposophic treatment 
modalities used were medications (88% of patients, n = 79/90); eurythmy therapy (22%); art 
therapy (10%); and rhythmical massage therapy (1%). Median number of eurythmy/art/massage 
sessions was 12 (interquartile range 10–20), median therapy duration was 120 days (84–184). 
From baseline to 12-month follow-up, all outcomes improved significantly (P  0.001 for all 
comparisons). Average improvements were: average asthma severity 2.61 points (95% confidence 
interval CI: 1.90–3.32); cough 0.93 (95% CI: 0.60–1.25); dyspnea 0.92 (95% CI: 0.56–1.28); 
exertion-induced symptoms 0.95 (95% CI: 0.64–1.25); frequency of asthma attacks 0.78 (95% CI: 
0.41–1.14); awakening from asthma 0.90 (95% CI: 0.58–1.21); AQLQ overall score 1.44 (95% CI: 
0.97–1.92); and KINDL asthma module 14.74 (95% CI: 9.70–19.78). All improvements were 
maintained until last follow-up after 24 months.
Conclusions: Patients with asthma under anthroposophic treatment had long-term improvements 
of symptoms and quality of life.
Keywords: anthroposophy, art therapy, asthma, combined modality therapy, drug therapy, 
eurythmy therapy, prospective studies, quality of life
Background
Asthma affects more than 10% of the population in developed countries1 and is 
associated with disability, reduced quality of life, reduced work capacity, psychiatric 
comorbidity, increased healthcare use, and increased mortality.2,3
Even under optimized guideline-based therapy in clinical trials, asthma symptoms 
remain poorly controlled in a proportion of patients,4,5 and many patients with asthma 
use complementary therapies,6 which are sometimes provided by their physicians.
Anthroposophic medicine (AM) is a complementary therapy system founded 
by Rudolf Steiner and Ita Wegman7 and provided by specially trained physicians 
in 56 countries worldwide.8 AM acknowledges a spiritual–existential dimension in 
man, which is assumed to interact with psychological and somatic levels in health Journal of Asthma and Allergy 2009:2 112
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and disease. AM therapy for asthma aims to counteract 
constitutional vulnerability, stimulate salutogenetic self-
healing capacities, and strengthen patient autonomy.9–14 The 
AM approach differs from conventional treatment in the use 
of special therapies (eurythmy movement exercises, art ther-
apy, rhythmical massage therapy) and special medications.
Eurythmy therapy is an artistic exercise therapy involving 
cognitive, emotional and volitional elements.15 In eurythmy 
therapy sessions the patients are instructed to exercise 
specific movements with the hands, the feet or the whole 
body. Eurythmy movements are related to the sounds of 
vowels and consonants, to music intervals or to soul gestures, 
eg, sympathy–antipathy. A eurythmy therapy cycle usually 
consists of 12–15 sessions of 45 min each, administered once 
weekly.16 Between therapy sessions the patients exercise 
eurythmy movements daily. In AM art therapy the patients 
engage in painting, drawing, clay modeling, music or speech 
exercises. An AM art therapy cycle usually consists of 
12 sessions of 45 min each, administered once weekly.17 
Rhythmical massage therapy was developed from Swedish 
massage; special techniques include lifting movements, 
rhythmically undulating gliding movements, and complex 
movement patterns like lemniscates. A rhythmical massage 
therapy cycle usually consists of 6–12 sessions administered 
once or twice weekly, each session lasting 20–30 min and 
followed by a rest period of at least 20 min.18 Most patients 
can be treated with one cycle of art, eurythmy or massage 
therapy, while prolonged treatment may be necessary 
for some patients with severe or persistent disease. AM 
medications are prepared from plants, minerals, animals, 
and from chemically defined substances. A key concept 
of AM medication therapy is typological correspondences 
between pathophysiological processes in man and formative 
forces working in minerals, plants and animals, reflecting a 
common evolution of man and nature.19 All AM medica-
tions are manufactured according to Good Manufacturing 
Practice and national drug regulations; quality standards of 
raw materials and manufacturing methods are described in 
the Anthroposophic Pharmaceutical Codex.20 The available 
evidence suggests that AM medications and therapies are 
generally well tolerated, with infrequent adverse reactions 
of mostly mild to moderate severity.21,22
Related to the AM approach is an educational philosophy 
implemented in more than 3,000 Waldorf Schools, 
kindergartens, and curative education centers worldwide.23,24 
Waldorf school attendance has been associated with a 
reduced risk for atopy,25,26 possibly mediated by effects on 
the intestinal microflora from restrictive use of antibiotics 
and antipyretics in childhood infectious disease26 or from a 
diet containing fermented vegetables.27
AM therapy is provided by physicians (counseling, 
AM medication) and nonmedical therapists (eurythmy, art, 
rhythmical massage). For patients with asthma the physician 
will choose among the available AM therapy modalities in 
order to tailor the treatment to individual disease features 
and the patient’s constitution. Initially, AM physicians will 
start AM treatment and optimize conventional therapy to 
achieve optimal symptom control. Subsequently, use of 
conventional medications may be slowly reduced while 
supervising controlling lung function. AM treatment will 
aim for optimal asthma control while keeping the use of 
conventional medication therapy as low as possible.13,14
A few mono- or bi-centric studies have evaluated AM 
medications28,29 or comprehensive AM therapy30,31 for asthma 
in inpatient hospitals,29,30 outpatient clinics,28,30,31 and practice 
settings.31 Here we present a pre-planned subgroup analysis 
of asthma patients from a multicenter study of comprehensive 
AM treatment in office-based settings.32
Methods
study design and objective
This is a prospective cohort study in a real-world medical 
setting. The study was part of a research project on the 
effectiveness, costs, and safety of AM therapies in outpatients 
with chronic disease (Anthroposophic Medicine Outcomes 
Study [AMOS]).32,33 The AMOS project was initiated by 
a health insurance company in conjunction with a health 
benefit program. The present pre-planned analysis concerned 
the subgroup of patients treated for asthma. Since this was 
one of the first prospective studies of comprehensive AM 
treatment for this indication in a Western office-based 
multicenter setting,21 the primary objective was to describe 
the AM therapy (spectrum of AM therapy modalities used, 
extent of combination with conventional asthma therapy) as 
well as the clinical outcome under AM treatment. Further 
research questions addressed the use of health services, 
adverse reactions, and therapy satisfaction.
setting, participants, and therapy
All physicians certified by the Physicians’ Association for 
Anthroposophical Medicine in Germany and working in 
an office-based practice or outpatient clinic were invited to 
participate in the study. Certification as an AM physician 
required a completed medical degree and a three-year 
structured postgraduate training. The participating physi-
cians recruited consecutive patients starting AM therapy. Journal of Asthma and Allergy 2009:2 113
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Patients enrolled in the period from January 1st, 1999 to 
December 31st, 2005 were included in the present analysis if 
they fulfilled the eligibility criteria. Inclusion criteria were:
1.  Outpatients aged 2–70 years.
2.  A clinical diagnosis of asthma (International Statistical 
Classification of Diseases and Related Health Problems, 
10th revision [ICD-10] J45).
3.  Starting AM therapy for asthma:
    •   AM-related consultation of at least 30 minutes followed 
by new prescription of AM medication,
    •    OR new referral to AM therapy (art, eurythmy, or 
rhythmical massage).
Patients were excluded if they had previously received 
the AM therapy in question for asthma. Patients were treated 
at the physicians’ discretion; physicians were thus free to 
individualize treatment. AM treatment was evaluated as a 
whole system.34
clinical outcomes
Primary outcome was average asthma severity, assessed on a 
numerical rating scale35 from 0 (“not present”) to 10 (“worst 
possible”), at 12-month follow-up. A 12-month follow-up 
period was chosen for the primary outcome assessment to 
eliminate any seasonal symptom variation.
Secondary clinical outcomes were asthma symptoms, 
symptom score, and quality of life. Asthma symptoms in 
the past three months (at baseline: in the past 12 months) 
were assessed on Likert scales from 1 (no symptoms) to 
4 (maximum symptoms) (adapted from Wjst and Wichmann36 
and Weiland and colleagues37):
•  Cough, dyspnea, exertion-induced symptoms: “no”, 
“little”, “medium”, “severe”.
•  Frequency of asthma attacks: “never”, “up to once per 
month”, “up to once per week”, “several times weekly”.
•  Awakening from asthma at night: “never”, “less than one 
night per week”, “1–3 nights per week”, “4 nights per 
week”.
Symptom score, the severity of one to six most relevant 
symptoms present at baseline, was assessed on numerical 
rating scales35 from 0 (“not present”) to 10 (“worst 
possible”).
In adults aged 17–70 years, asthma-related quality of life 
was assessed with the Asthma Quality of Life Questionnaire 
(AQLQ).38 The AQLQ comprises an overall score and the 
subscales activity limitations, symptoms, emotional function, 
and exposure to environmental stimuli. Each AQLQ score 
ranges from 1 (maximal impairment) to 7 (no impairment). 
AQLQ score changes are classified as minimally important 
(0.5–1.0 points), moderate (1.0–1.5 points) and large 
(1.5 points).39 Generic quality of life in adults was assessed 
by the Short-Form, 36 question (SF-36®) Health Survey40 
(physical and mental component summary measures).
In children aged 3–16 years, quality of life was assessed 
with the KINDL® Questionnaire for Measuring Health-
Related Quality of Life in Children and Adolescents41 
(asthma module and total quality of life score, 0–100).
All clinical outcomes were documented by patients 
(or caregivers of children) on questionnaires after 0, 3, 6, 12, 
18, and 24 months. Asthma symptoms, AQLQ, and KINDL 
were documented in patients enrolled after March 2001.
Other outcomes
Therapy outcome rating (0–10) and satisfaction with therapy 
(0–10) were documented by patients or caregivers after six 
and 12 months.
Adverse reactions to medications or therapies were 
documented by the patients after six, 12, 18, and 24 months and 
by the physicians after six months. The documentation included 
suspected cause, intensity (mild, moderate, severe = no, some, 
complete impairment of normal daily activities), and therapy 
withdrawal because of adverse reactions. Serious adverse 
events (death, life-threatening condition, acute in-patient 
hospitalization, new disease or accident causing permanent 
disability, congenital anomaly, new malignancy) were 
documented by the physicians throughout the study. Adverse 
events and reactions occurring in patients enrolled until 
March 2001 were included in a detailed safety analysis of 
AM medications in the AMOS study.42
Use of adjunctive therapies and health services in 
the pre-study year was documented at study entry, use 
in the first study year was documented after six and 
12 months, and use in the second study year was docu-
mented after 18 and 24 months. The following items were 
documented: physician or dentist visits, diagnostic investi-
gations (X-rays, computer tomography, magnetic resonance 
imaging, scintigrams), non-AM medications, physiotherapy, 
psychotherapy, inpatient hospital and rehabilitation 
treatment, surgery, asthma-related surgery, and sick leave. 
Use of conventional asthma medication (Anatomical Thera-
peutic Chemical Classification Index H02, J01, J04, J07A, 
L03, R03, R06–07, see Table 1) in the pre-study year and 
in months 0–12 was analyzed separately.
Data collection
All data were documented with questionnaires. Questionnaires 
used at study enrolment were handed out by the physicians; Journal of Asthma and Allergy 2009:2 114
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follow-up questionnaires were administered from the study 
office by post. All questionnaires were returned in sealed 
envelopes to the study office. Physicians documented 
eligibility criteria; all other items were documented by patients 
(by caregivers of children 17 years) unless otherwise 
stated. The patient responses were not made available to the 
physicians. Medication use was documented with name of 
medication, administration frequency (daily, 3–6 days per 
week, 1–2 days per week, 1–3 days per month, 1 day per 
month), and duration of use.
The physicians were compensated €40 (after March 2001: 
€60) per included and fully documented patient, while the 
patients received no financial compensation.
The data were entered twice by two different persons 
into Microsoft® Access 97 (Microsoft Corp., Redmond, WA, 
USA). The two datasets were compared and discrepancies 
resolved by checking with the original data.
Quality assurance, adherence 
to regulations
The study was approved by the Ethics Committee of the 
Faculty of Medicine Charité, Humboldt University, Berlin, 
Germany, and was conducted according to the Declaration of 
Helsinki and largely following the ICH Guidelines for Good 
Clinical Practice E6. Written informed consent was obtained 
from all patients before enrolment.
Data analysis
The data analysis was performed on all patients fulfilling the 
eligibility criteria, using SPSS® 17.0 (SPSS Inc., Chicago, 
Ill, USA) and StatXact® 5.0.3 (Cytel Software Corporation, 
Cambridge, MA, USA). For univariate comparisons of 
continuous data with normal distribution t-test for paired 
samples was used for paired samples and t-test for independent 
samples was used for independent samples; Wilcoxon signed-
rank test was used for paired continuous data with nonnormal 
distribution; McNemar test and Fisher’s exact test were used for 
dichotomous data. All tests were two-tailed. Clinical outcomes 
were analyzed with 0–12 month and 0–24 month pre–post 
comparisons. In addition, repeated measures analysis of vari-
ance (ANOVA) was performed, testing for within-subject 
change between the time points 0–3–6–12 months and 
0–18–24 months, respectively. If Mauchly’s test of sphericity 
was significant, Greenhouse–Geisser epsilon adjustment was 
performed.43 Significance criterion was P  0.05. Since this 
was a descriptive study, no adjustment for multiple comparisons 
was performed.44 Pre–post effect sizes were calculated as 
standardized response mean (= mean change score divided by 
the standard deviation of the change score) and classified as 
minimal (0.20), small (0.20–0.49), medium (0.50–0.79), and 
large (0.80).45,46 In the main analysis, clinical outcomes were 
analyzed in patients with evaluable data for each follow-up, 
without replacement of missing values.
Table 1 Use of conventional asthma medication
Medications (Anatomical   Therapeutic 
Chemical Classification Index)
Prestudy year Months 0–12
Patients Total days Patients Total days
N % N %
Any asthma medication 38 72% 12,215 31 58% 11,278
  • H02 corticosteroids for systemic use 5 9% 457 2 4% 8
  •  J01 Antibacterials for systemic use 7 13% 344 4 8% 48
  •  R03A Adrenergics, inhalants 25 47% 4,322 28 53% 4,762
  •  R03BA glucocorticoids 12 23% 3,214 16 30% 4,012
  •  R03BB Anticholinergics 0 0% 0 1 2% 120
  •  R03Bc Antiallergic agents 7 13% 1,019 5 9% 640
  •  R03c Adrenergics for systemic use 1 2% 90 0 0% 0
  •    R03D Other systemic drugs for 
obstructive airway diseases
10 19% 2,278 10 19% 2,204
  •  R06 Antihistamines for systemic use 7 13% 491 7 13% 220
  •  Other:  J04, J07A, L03, R03BX 0 0% 0 0 0% 0
no asthma medication 15 28% 0 22 42% 0
Total (evaluable patients) 53 100% 53 100%
Notes: evaluable patients: patients with evaluable data on medication use at baseline and at 3-, 6-, and 12-month follow-up.Journal of Asthma and Allergy 2009:2 115
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Two pre-planned sensitivity analyses (SA1–SA2) 
were performed to assess the influence of patient attrition 
(SA1) and conventional antiasthma therapies (SA2) on the 
0–12-month outcome of average asthma severity. In SA1 
missing values after 12 months were replaced with the last 
value carried forward. In SA2 the sample was restricted to 
patients not using conventional asthma medications except 
adrenergic inhalants and not having asthma-related surgery 
during the first 12 study months. Post-hoc subgroup analyses 
were performed on evaluable subgroups (age, AM therapy 
modality, number of patients enrolled per physician).
Results
Participating physicians and therapists
The patients were enrolled by 36 physicians (26 general 
practitioners, eight pediatricians, and two internists). Compar-
ing these physicians to AM-certified physicians in Germany 
with the same qualifications but without study patients 
(n = 311), no significant differences were found regarding age 
(mean ± standard deviation: 46.5 ± 6.7 vs 48.3 ± 8.1 years), 
gender (72.2% vs 58.8% male), number of years in practice 
(17.3 ± 7.0 vs 19.3 ± 8.8 years) or the proportion of primary 
care physicians (94.4% vs 94.4%).
The patients were treated by 31 different AM therapists 
(art, eurythmy, rhythmical massage). Comparing these thera-
pists to certified AM therapists in Germany without study 
patients (n = 1137), no significant differences were found 
regarding gender (71.0% vs 81.4% females), age (mean 
50.2 ± 7.8 vs 50.2 ± 9.5 years) or the number of years since 
therapist qualification (13.8 ± 6.9 vs 13.1 ± 8.7 years).
Patient recruitment and follow-up
A total of 95 patients starting AM therapy for asthma were 
assessed for eligibility. Of these patients, 90 fulfilled all 
eligibility criteria and were included in the analysis. Five 
patients were not included, for the following reasons: patients’ 
and physicians’ baseline questionnaire dated 30 days apart 
(n = 4), no informed consent (n = 1).
A total of 44% (n = 40/90) of patients were enrolled by gen-
eral practitioners, 41% (n = 37) by internists, and 14% (n = 13) 
by pediatricians. The physicians’ settings were primary care 
practices (53% of evaluable patients, n = 47/88), referral prac-
tices (41%, n = 36), and outpatient clinics (6%, n = 5). A total 
of 31 physicians enrolled 1–2 patients each, four physicians 
enrolled 3–5 patients each, and one physician specializing in 
AM asthma therapy enrolled 36 patients.
The last patient follow-up ensued on November 10th, 
2007. A total of 92% (n = 83/90) of patients returned at least 
one follow-up questionnaire. The patients were administered 
a total of 450 questionnaires, out of which 324 (72%) were 
returned. Follow-up rates were 83% (n = 75/90), 72% 
(n = 65), 74% (n = 67), 64% (n = 58), and 66% (n = 59) after 
3, 6, 12, 18, and 24 months, respectively. Respondents and 
nonrespondents of the 12-month patient-follow-up did not 
differ significantly regarding age, gender, disease duration 
or baseline parameters (average asthma severity, symptom 
score, AQLQ overall score). Comparisons of respondents 
(n = 43) and nonrespondents (n = 18) of the 24-month 
follow-up also showed no significant differences for these 
parameters. The physician six-month follow-up documenta-
tion was available for 89% (n = 80/90) of patients.
numbers analyzed
The numbers analyzed for major subgroups and follow-up 
periods are presented in Table 2.
Baseline characteristics
The patients were recruited from nine of 16 German 
federal  states. The  sample  comprised  36  children 
(aged 2–16 years) and 54 adults (aged 18–68 years). Age 
groups were 2–19 years (41%, n = 37/90), 20–39 years 
(21%, n = 19), 40–59 years (31%, n = 28), and 60–70 years 
(7%, n = 6) with a median age of 33.8 years (interquar-
tile range [IQR] 9.2–44.8 years, range 2–68 years, mean 
29.5 ± 19.5 years). A total of 36% (n = 13/36) of the children 
and 70% (n = 38/54) of the adults were women.
Compared with the German population, adult patients 
had higher educational and occupational levels and were less 
frequently unemployed, living alone, regular smokers, and 
daily alcohol consumers; sociodemographic status was similar 
to the population regarding the proportion with overweight 
or living on a low income as well as work disability pension 
and severe disability status; while the number of sick-leave 
days in the past year was higher in study patients than in the 
population (Table 3).
The disease duration was 1 year in 6% (n = 5/90) 
of patients, 1–4 years in 37% (n = 33), and 5 years in 
58% (n = 52), with a median disease duration of 5.0 (IQR 
1.0–10.0 years, mean 10.1 ± 10.6 years). A total of 96% 
(n = 52/54) of adults had a disease duration of 1 year.
A current comorbid disease was present in 81% (n  = 73/90) 
of patients, with a median of 1 (IQR 1–3) comorbid diseases 
per patient. Most common comorbid diseases, classified by 
ICD-10, were J30 vasomotor and allergic rhinitis (15.9%, 
n = 23 of 145 diagnoses), J32 chronic sinusitis (7.6%), and 
L20 atopic dermatitis (7.6%).Journal of Asthma and Allergy 2009:2 116
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Further baseline data on asthma were documented in 
patients enrolled after March 2001 (Table 4): A total of 56% 
(n = 35/62) of these patients had only intermittent symptoms 
with asthma attacks  once per month and awakening from 
asthma 1 night per week.
Therapy
At study enrolment, the duration of the consultation with the 
AM physician was 30 min in 24% (n = 22/90) of patients, 
30–44 min in 31%, 45–59 min in 29%, and 60 min in 
16% of patients. At enrolment 60% (n = 54/90) of patients 
were prescribed AM medication by the physician, while the 
remaining 40% (n = 36) were referred to eurythmy therapy, 
AM art therapy, or rhythmical massage therapy (eurythmy/
art/massage therapy). Of these 36 patients, 83% (n = 30) 
had the planned AM therapy, 3% (n = 1) did not have AM 
therapy, and for 14% (n = 5) the AM therapy documentation 
is incomplete. AM therapies used were eurythmy therapy 
(n = 20), rhythmical massage therapy (n = 1), and AM art 
therapy (n = 9) with the therapy modalities painting/drawing/
clay (n = 4), music (n = 3), and speech exercises (n = 2). 
The AM eurythmy/art/massage therapy started median 
14 (IQR 0–32) days after enrolment. Median therapy dura-
tion was 120 days (IQR 84–184 days), median number of 
therapy sessions was 12 (IQR 10–20). AM medications were 
used by 88% (n = 79/90) of patients. The most frequently 
used AM medications in month 0–12 (different dosage 
forms and concentrations grouped together) were Heracleum 
mantegazzianum (n = 31 patients), Tabacum Cupro cultum 
(n = 31), Quartz (n = 30), Tartarus stibiatus (n = 11), 
Argentum/Echinacea (n = 10), and Gencydo (n = 10).
The use of adjunctive therapies, health services, and sick 
leave was compared between the pre-study year and the first 
and second years, respectively. One significant change was 
found: The number of physician/dentist visits decreased from 
average 20.6 ± 52.4 visits in the pre-study year to 12.2 ± 17.1 
visits in the first year (P = 0.001) and 12.5 ± 12.7 visits 
in the second year (P = 0.001). No other items (non-AM 
medications, physiotherapy, psychotherapy, diagnostic 
investigations, inpatient hospital or rehabilitation treatment, 
surgery or sick leave) changed significantly in any period.
The use of conventional asthma therapy in the 
pre-study year and in months 0–12 was analyzed separately. 
Conventional asthma medications were used by 72% 
(n = 38/53) of evaluable patients in the pre-study year, and 
by 58% (n = 31/53) in months 0–12 (P = 0.039). The most 
frequently used medications in months 0–12, classified by 
the Anatomical Therapeutic Chemical Classification Index, 
were R03A adrenergics, inhalants (53%, n = 28/53 patients), 
R03BA glucocorticoids (30%, n = 16/53). Further data 
on conventional asthma medications are presented in 
Table 1. Asthma-relevant surgery occurred in one patient in 
the pre-study year and in one patient in months 0–12 (nasal 
polyp surgery in both cases).
Table 2 numbers analyzed
Patient group Month 0 Month 12 (Table 5) Month 24 (Table 7)
N Analysis N* Analysis N* Analysis
All patients 90 Disease status at 
baseline (text)
67 Average asthma severity 
(see also Table 6), 
symptom score
59 Average asthma 
severity, symptom 
score
All patients 53 [Months 3 + 6 + 12] Use 
of conventional asthma 
medication (Table 1)
Adults  
(aged 18–68 years)
54 sociodemographics 
(Table 3)
38 sF-36 35 sF-36
children  
(aged 2–16 years)
36
Patients recruited 
after March 2001
65 Disease status at 
baseline (Table 4)
Asthma symptoms Asthma symptoms
Adults recruited 
after March 2001
42 26 AQLQ 25 AQLQ
children recruited 
after March 2001
23 16 KinDL 15 KinDL
Abbreviations: n*, refers to number of patients returning the respective follow-up questionnaire; the corresponding number with evaluable data for an individual outcome 
may be lower;   AQLQ, Asthma Quality of Life Questionnaire; KinDL, Questionnaire for Measuring Health-Related Quality of Life in children and Adolescents; sF-36, short-
Form Health survey (36 items).Journal of Asthma and Allergy 2009:2 117
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clinical outcomes
In months 0–12 all 16 clinical outcomes improved significantly 
from baseline in the 0–12 month prepost comparison as 
well as in the 0–3–6–12 month ANOVA (Table 5). Most 
improvements occurred in months 0–6 (Figures 1–5). 
At 12-month follow-up an improvement of 50% of baseline 
average asthma severity was observed in 59% (n = 39/66) 
of evaluable patients; in adults the AQLQ overall score 
showed a minimally important improvement of 0.5–1.0 
points in 20% (n = 5/25) of evaluable patients, a moderate 
improvement of 1.0–1.5 points in 28% (n = 7), and a large 
improvement of 1.5 points in 38% (n = 9). Standardized 
response mean effect sizes for the 0–12 month comparison 
were large for 10 scores, medium for two, and small for one 
score (Table 5).
Subgroup analyses of the 0–12 month pre–post 
comparison of average asthma severity (Table 6) showed 
significantly more improvement in children than in adults 
(mean difference 1.69 points, 95% confidence interval 
[CI]: 0.31–3.07; P = 0.017). No significant difference in 
improvement was found between patients enrolled for 
medical therapy or referred to eurythmy/art/massage therapy 
(P = 0.214) or when patients were grouped according to the 
number of patients enrolled per physician (1–5 patients vs 
36 patients: P = 0.551).
We performed two sensitivity analyses of the 0–12-month 
outcome of average asthma severity (Table 6: SA1–SA2; see 
Methods for further description). SA1 alone resulted in a 
reduction of the average improvement of 13% (2.61→2.28 
points) while SA2 alone and SA1+SA2 in combination had 
only minimal effects.
In months 18–24, a total of 14 of the 16 clinical outcomes 
were significantly improved from baseline in the 0–24 month 
pre–post comparison as well as in the 0–18–24 month 
ANOVA, SF-36 mental component was significantly 
improved in the 0–18–24 month ANOVA only, and KINDL 
total score (n = 12 patients) was not improved in any analysis 
(Table 7).
Other outcomes
At six-month follow-up, patients’ therapy outcome rating 
(numeric scale from 0 “no help at all” to 10 “helped very 
well”) was average 7.54 ± 2.44 and patient satisfaction with 
therapy (from 0 “very dissatisfied” to 10 “very satisfied”) was 
8.19 ± 2.12. The ratings of therapy outcome and satisfaction 
did not differ significantly between adults (patient rating) and 
children (proxy rating by caregivers) nor between six- and 
12-month follow-up.
The frequency of reported adverse drug reactions was 6% 
(n = 5 of 79 users) for reactions with a suspected relation to 
Table 3 sociodemographic data of adult patients
Item Subgroups Study patients German population References
N % %
education72 Low (level 1 ) 6/54 11% 43% 73
intermediate (level 2) 25/54 46% 43%
High (level 3) 23/54 43% 14%
Wage earners economically active patients 1/36 3% 18% 74
Unemployed during last 12 months economically active patients 0/36 0% 10% 74
Living alone 7/54 13% 21% 74
net family income  €900 per month 4/46 9% 16% 74
Alcohol use daily (patients) vs almost 
daily (germany)
Male 1/16 6% 28% 75
Female 1/38 3% 11%
Regular smoking Male 2/16 13% 37% 76
Female 2/38 5% 28%
sports activity 1 hour weekly Age 25–69 years 25/50 50% 39% 77
Body mass index 25 (overweight) Male 7/16 44% 56% 74
Female 15/37 41% 39%
Permanent work disability pension 4/54 7% 3% 78
severe disability status 5/54 9% 12% 79
sick leave days in the last 12 months 
(mean ± sD)
economically active patients 29.2 ± 38.3 17.0 80
Abbreviation: sD, standard deviation.Journal of Asthma and Allergy 2009:2 118
Hamre et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
AM medications and 24% (n = 16 of 67 users) for reactions 
with a suspected relation to non-AM medications (P = 0.004). 
Adverse drug reactions of severe intensity were reported in 
five patients (AM medications: n = 1, non-AM medications: 
n = 4), while medication was stopped due to reported adverse 
drug reactions in eight patients (AM medications: n = 2, 
non-AM medications: n = 6). Of the five reported adverse 
reactions with a suspected relation to AM medications, two 
reactions occurred in patients enrolled before March 2001 
and these two patients were included in a detailed safety 
analysis of AM medications in the AMOS study.42 For reaction 
1, the causal relationship to AM medication was confirmed 
(moderate injection-site reaction to Gencydo injections); for 
reaction 2, the causal relationship to AM medication was not 
confirmed (severe symptom aggravation following temporary 
dose reduction of conventional antiasthma medication). 
Reactions 3–5 occurred in patients enrolled after March 2001 
and were not included in the safety analysis (reaction 3: mild 
symptom aggravation; reaction 4: moderate fever; reaction 
5: moderate symptom aggravation). Adverse reactions from 
AM eurythmy/art/massage therapy were reported by one (3%) 
of 30 therapy users. The reported reaction was an increased 
number of asthma attacks following AM art therapy with 
painting exercises. This reaction was of moderate intensity 
and did not require the painting exercises to be stopped.
Two serious adverse events occurred: One patient had 
surgery for life-threatening adhesive ileus, and one patient 
was acutely hospitalized for pneumonia. None of these events 
were causally related to any therapy or medication.
Discussion
The aim of this prospective cohort study was to obtain 
information on comprehensive AM therapy for asthma 
under routine outpatient conditions in Germany. Children 
and adults starting AM therapy for asthma were included: 
eight of nine patients used AM medications and one-fourth 
used eurythmy therapy. Under AM treatment, significant and 
sustained improvements of asthma symptoms and quality of 
life were observed.
Strengths of this study include a detailed assessment 
of the therapy setting and therapy-related factors, a long 
follow-up period, and high representativeness: 10% of all 
AM-certified physicians seeing asthma patients in Germany 
participated; the participating AM physicians and therapists 
resembled all eligible physicians and therapists with respect 
to socio-demographic characteristics; and 95% of screened 
patients were enrolled. These features suggest that the study 
mirrors contemporary AM practice in office-based settings 
to a high degree.
To assess the routine clinical practice, where the selection 
of AM therapy options will vary according to individual 
needs, we analyzed AM as a whole system.34 Supplementary 
subgroup analyses were possible and showed significant 
improvements in patients receiving AM medical therapy, 
AM eurythmy/art/massage therapy, and eurythmy therapy 
alone. However, the sample size for AM art therapy and 
rhythmical massage therapy did not allow for separate 
analysis of these subgroups. The influence of other therapy 
variables (eg, duration of the consultation with the physician 
at study enrolment, number of AM therapy sessions) on 
clinical outcomes has been assessed in multivariate analyses 
of children47 and adults (submitted for publication) in AMOS 
with asthma and other chronic indications.
Table 4 Disease status at baseline
Item N %
Asthma diagnosis definite 64/65 98%
Asthma diagnosis based on pulmonary 
function tests or examination by 
pulmonologist
60/65 92%
Associated diseases (ever had)
  Allergic rhinitis 34/61 56%
  Atopic dermatitis 21/59 36%
  Other allergic disease 38/62 61%
symptoms in past 12 months
  Wheeze 51/61 84%
  Dry cough at night 46/62 74%
  Difficulty breathing 43/61 70%
  Wheeze on exertion 47/61 77%
seasonal asthma symptoms (yes) 44/62 71%
Frequency of asthma attacks in past 
12 months
  once per month 39/62 63%
  once weekly 6/62 10%
  several times weekly 17/62 27%
Awakening from asthma attacks at night
  1 night per week 39/62 63%
  1–3 nights per week 10/62 16%
  4 nights per week 13/62 21%
emergency room or inpatient treatment 
for asthma in past 12 months
8/62 13%
ces-D  24 points = depressive range 12/52 23%
Notes: These items were documented in patients enrolled after March 2001 (n = 65). 
Asthma diagnosis documented by physicians, other items by patients or caregivers.
Abbreviations: ces-D, center for epidemiological studies Depression scale, 
german version.71Journal of Asthma and Allergy 2009:2 119
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Inclusion criterion for this study was a clinical diagnosis 
of asthma. For logistical reasons it was not possible to 
have the diagnosis confirmed by performing pulmonary 
function tests on all patients prior to enrolment. However, 
in 98% of patients the physician classified the asthma 
diagnosis as ‘definite’ and in 92% the diagnosis had been 
confirmed by pulmonary function tests or by examination 
by pulmonologists (assessed in patients enrolled after March 
2001, 72% of the whole sample). A relevant confounding of 
the sample by inclusion of nonasthmatic subjects therefore 
seems unlikely.
Since the study had a long recruitment period, the study 
physicians were not able to participate throughout the period 
and to screen and enrol all eligible patients (criteria: see 
Methods section). For a different subset of patients from 
the AMOS project (patients referred to AM therapies for 
any chronic indication and enrolled before April 1st, 2001), 
it was estimated that physicians enrolled every fourth eligible 
patient.48 This selection could bias results if physicians were 
able to predict therapy response and if they preferentially 
screened and enrolled such patients for whom they expected a 
particularly favorable outcome. In this case one would expect 
the degree of selection (the proportion of eligible vs enrolled 
patients) to correlate positively with clinical outcomes. That 
was not the case, the correlation was almost zero (-0.04). 
This analysis48 does not suggest that physicians’ screening 
of eligible patients was affected by selection bias.
A limitation of the study is the absence of a comparison 
group receiving conventional treatment or no therapy. 
Accordingly, one must consider several other causes for the 
observed improvements apart from the AM treatment. We 
conducted a sensitivity analysis of average asthma severity, 
estimating the influence of attrition bias and adjunctive 
treatment with asthma medications or surgery. These two 
factors together explained up to 13% of the 0–12 month 
improvement. Natural recovery from asthma appears 
unlikely in adult patients with long disease duration49 and 
96% of adults had a disease duration of at least one year, 
but long-term natural recovery is not uncommon in children 
with asthma.50,51 Regression to the mean due to symptom 
fluctuation with preferential self-selection to therapy and 
study inclusion at symptom peaks is another possibility: 
according to a previous analysis of mixed diagnoses from 
the AMOS project,49 this phenomenon explained up to 
0.43 points (15%) of the 0–6 month improvement of an 
outcome corresponding to average asthma severity in this 
analysis. Seasonal variations in asthma symptoms would 
be expected to be leveled out by analyzing outcomes at 
12-month follow-up. Other possible confounders are 
psychological factors and nonspecific effects (eg, placebo 
effects, context effects, physician-patient interactions, 
patient expectations, social desirability effects). However, 
since AM therapy was evaluated as a whole system,34 the 
question of specific therapy effects vs nonspecific effects 
was not an issue of the present analysis. Nonetheless, the 
lack of objective outcomes, such as pulmonary function 
tests, to supplement the subjective outcomes is a limitation 
of the study.
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This study comprised 16 outcome measures, each 
analyzed with two different methods at two follow-up 
assessments, a total of 64 analyses (Tables 5 and 7). We did 
not use P-value adjustment for multiple testing, which is a 
limitation in regard to the risk of finding significant results 
by chance (type-I-error). However, the problem of multiple 
testing has no universal solution, as P-value adjustment 
will increase the risk of making type-II errors.44 Another 
approach, used for the present analysis, is to have one single 
pre-defined primary outcome44 (average asthma severity 
at 12-month follow-up). Regarding secondary outcomes 
(a total of 62 analyses), 59 P-values indicated significant 
improvements and 43 P-values were 0.001 – a constellation 
that would not be expected to occur by chance.
Apart from one analysis of 20 children,31 this study provides 
the first data on comprehensive AM treatment for asthma in 
Western European office-based settings. The predominance 
of women among adult study patients is in accordance with 
data from German primary care,52 while the proportion of 
patients who reported only intermittent asthma symptoms 
(56%) was twice as high as in German primary care.52,53 
The low proportion of patients using inhaled corticosteroids 
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(30%) or any conventional antiasthma-medications (58%) 
in months 0–12 could be related to the low self-reported 
asthma severity. Furthermore, both asthma severity (assessed 
by symptom frequency) and medication use may have been 
under-reported due to recall bias.54 The daily dosage of 
inhaled corticosteroids was not documented and can therefore 
not be compared to other studies.
In adult patients, asthma-related quality of life at 
baseline, assessed with the AQLQ overall score (4.0 points), 
was one-third standard deviation worse than average in a 
German multicenter primary care cohort of asthma patients 
(4.4 points).53 In this multicenter cohort, AQLQ overall 
score showed an inverse relation to asthma severity, with the 
baseline score value of the present study (4.0 points) falling 
between scores of patients with mild persistent (3.8 points) 
and moderate persistent asthma (4.6 points). In months 
0–12 of the present study, AQLQ overall score showed an 
improvement of 1.4 points, which is classified as a moderate 
improvement (1.0–1.5 points).39 In other evaluable asthma 
cohorts receiving other treatments, the corresponding 
0–12 month improvements were moderate,4,55–57 minimal 
(0.5–1.0 points)57–59 or not relevant (0.5 points).60–62 
In adult patients of the present study, generic quality of life, 
assessed with the SF-36 Health Survey, was similar to other 
asthma cohorts at baseline and improved similarly during 
follow-up.63 In children of the present study, generic quality of 
life at baseline, assessed with the KINDL total quality of life 
score, was two-third standard deviations worse than average 
score values in German children with asthma.64 In months 
0–12 of this study the KINDL total quality of life score 
improved similarly to 0–12 month improvements in asthma 
cohorts receiving other treatment,65,66 while KINDL asthma 
module was similar at baseline but showed more outspoken 
improvement in this study than in a cohort of children under-
going inpatient rehabilitation (difference of 0.9 standard 
deviations).67 To sum up: relative to other studies, our study 
patients had low self-reported asthma symptom severity but 
similar or more outspoken reduction of quality of life at base-
line. One consequence of the predominantly low symptom 
severity is that study results may not be generalizable to 
patients with high asthma severity. A low correlation between 
asthma symptoms and quality of life has been found in many 
studies.68 Quality of life improvements in our study were 
at least of the same order of magnitude as in other treated 
cohorts. Since data on airway caliber were not available in 
our study, a comparison to other studies is not possible.
Previous studies have found beneficial effects of AM 
medications28,29 or comprehensive AM therapy30,31 in 
children30,31 or adults28,29 with asthma. In accordance with 
these findings, our multicenter study showed sustained 
Table 6 Average asthma severity 0–12 months: subgroup and sensitivity analyses (sA)
Group/Analysis N 0 months 12 months T -test: 0–12 month difference
Mean (SD) Mean (SD) Mean (95% CI) P-value
Main analysis: Patients with available  
data at 0 and 12 months
66 5.35 (2.17) 2.74 (2.30) 2.61 (1.90–3.32) 0.001
Age groups
  •  children (2–16 years) 29 5.69 (2.24) 2.14 (2.07) 3.55 (2.45–4.65) 0.001
  • Adults (17–70 years) 37 5.08 (2.11) 3.22 (2.39) 1.86 (0.96–2.76) 0.001
Main anthroposophic therapy modality
  •  Medical 37 5.35 (2.15) 2.35 (1.99) 3.00 (2.17–3.83) 0.001
  •    eurythmy therapy, art therapy, or 
rhythmical massage therapy
29 5.34 (2.24) 3.24 (2.60) 2.10 (0.84–3.37) 0.002
  •  eurythmy therapy 21 5.19 (2.36) 3.14 (2.63) 2.05 (0.57–3.53) 0.009
Number of patients enrolled per physician
  •  1–5 patients (30 physicians) 44 5.43 (2.14) 2.98 (2.34) 2.45 (1.52–3.39) 0.001
  •  36 patients (one physician) 22 5.18 (2.28) 2.27 (2.21) 2.91 (1.80–4.02) 0.001
sA1: Last value carried forward 89 5.48 (2.14) 3.20 (2.51) 2.28 (1.69–2.87) 0.001
sA2: Patients not using asthma medications 
apart from adrenergic inhalants, and 
not having asthma-related surgery in 
months 0–12
28 5.93 (2.05) 3.39 (2.77) 2.54 (1.26–3.81) 0.001
sA1 + sA2 28 5.93 (2.05) 3.39 (2.77) 2.54 (1.26–3.81) 0.001
Abbreviations: CI, confidence interval; SD, standard deviation.Journal of Asthma and Allergy 2009:2 125
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improvement of asthma symptoms as well as generic and 
asthma-related quality of life in children and in adults under 
comprehensive AM treatment.
The AM approach evaluated in this study differs from 
many other therapies used for asthma in two aspects: 
Whereas in many complementary6,69 and conventional 
therapies the patient is essentially a passive user of products 
(eg, herbs, conventional medications) or recipient of 
treatments (eg, acupuncture), the AM approach involves 
active as well as passive therapies. Whereas other active 
therapies (eg, relaxation techniques) may be perceived 
as monotonous, the AM exercise therapies used by more 
than one-third of patients in this study allow for artistic 
movements (eurythmy) or expression (eg, painting, music), 
which may be welcome in some patients. Another favorable 
aspect of AM is its full integration with conventional 
medicine, allowing for the provision of all conventional 
and complementary treatment by one medical practitioner, 
thus avoiding communication difficulties and conflicts 
about disclosure of complementary treatment to providers 
of conventional asthma therapy.69
Future studies on AM treatment for asthma should include 
pulmonary function tests and a more detailed documentation 
of the AM therapy modalities (eg, for eurythmy therapy: 
the type of eurythmy exercises used and the frequency 
and duration of eurythmy home exercises). Studies with 
concurrent control groups would be desirable. However, it 
is difficult to conduct randomized trials in AM settings, as 
randomization is often rejected by AM physicians and their 
patients, chiefly due to strong therapy preferences.21, 22 One 
possible solution could be to recruit patients from outside 
AM settings and randomize them to immediate treatment 
in an AM setting or to a waiting-list control group.70 
Another possibility would be a nonrandomized system 
comparison of treatment by AM and conventional physicians 
with adjustment for baseline differences.71
Conclusion
Patients with asthma under AM treatment had long-term 
improvements of symptoms as well as asthma-related and 
generic quality of life. The improvements in quality of life 
scores were at least of the same order of magnitude as in 
asthma cohorts receiving other treatment. These findings are 
encouraging and warrant further research.
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